Back

Differences between hospitalised vs. outpatient management amongst european patients with atrial fibrillation: the EORP-AF general long-term registry

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Oral anticoagulants : news from large trials and registries Anticoagulants ESC Premium Access ESC Congress 2018

About the speaker

Photo
Associate Professor Marco Proietti

University of Milan, Milan (Italy)

5 More presentations in this session

Presentation thumbnail
Real-world clinical data of atrial fibrillation patients treated with direct oral anticoagulants in combination with or without antiplatelet therapy
Doctor R. Amiya (Osaka, JP)
Abstract Slides
Presentation thumbnail
Characterization of major and clinically relevant non-major bleeding in the APEX trial
Miss M. Yee (Boston, US)
Abstract Slides
Presentation thumbnail
Increased major bleeding risk with use of topical miconazole agents among users of oral anticoagulation: A population-level safety study
Doctor M. Lamberts (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Comparison of P2Y12 inhibitors in atrial fibrillation patients treated by dual-antiplatelet therapy without oral anticoagulant after acute myocardial infarction with percutaneous coronary intervention
Professor H. Jeong (Iksan, KR)
Abstract Slides
Presentation thumbnail
Oral anticoagulants in patients with atrial fibrillation and non-mechanical heart valve disease
Mr J. Strange (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Oral anticoagulants : news from large trials and registries

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources